In recent years diabetes is prevailing widely and has become matter of concern. Newer and newer drugs are coming to control diabetes. Recent introduction of Liraglutide seems to be promising.

Team@CMHF

Liraglutide, a once-daily human glucagon-like peptide-1 (GLP-1) analog, was approved by the US Food and Drug Administration in 2010 for the treatment of type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 enhances insulin secretion and inhibits glucagon in a glucose-dependent manner. The efficacy and safety of liraglutide were evaluated with sitagliptin and in another trial where basal insulin was added to liraglutide + metformin.

At liraglutide doses of 1.2 mg or 1.8 mg once daily, significant mean reductions in glycated hemoglobin (HbA1c) (1%–1.6%) and fasting plasma glucose (15–43 mg/dL), as well as sustained weight loss (2–3 kg) and a low rate of hypoglycemia occurred. Liraglutide provide an important expansion of options for the treatment of T2DM.

Reference: http://www.docguide.com/next-generation-glp-1-therapy-introduction-liraglutide?hash=80445d1a&eid=22199&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2